Figure 6.

Changing tumor immune microenvironment by FUVAC infection

(A) Schedule of the immune microenvironment characterization after MDRVV or FUVAC treatment. Bilateral CT26-bearing mice were treated with MDRVV or FUVAC using the same method as Figure 4. 5 days after the first virus injection (1 day after the third injection), the virus-treated or -untreated tumors were recovered and processed for flow cytometry analysis. (B) The ratio of CD45⁺ total immune cells and total tumor cells, and the ratio of CD3⁺ T lymphocyte in CD45⁺ cells. (C) The ratios of CD3⁺/CD8⁺ and CD3⁺/CD4⁺ cells in CD45⁺ T lymphocyte, and the ratio of Treg in CD3⁺ T cell as determined by the expression levels of CD4, CD25, and FoxP3. (D) The ratio of TAM (CD11b⁺ F4/80⁺), M-MDSC (CD11b⁺ Ly6C⁺), or G-MDSC (CD11b⁺ Ly6C^– Ly6G⁺) in CD45⁺ cells. Data in (B)–(D) are presented as the means ± SEM (n = 7). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (two-tailed unpaired t test).